Bridgeway Capital Management LLC Sells 253,287 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Bridgeway Capital Management LLC reduced its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 60.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 166,200 shares of the biopharmaceutical company’s stock after selling 253,287 shares during the period. Bridgeway Capital Management LLC’s holdings in Vanda Pharmaceuticals were worth $796,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of VNDA. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Vanda Pharmaceuticals in the 4th quarter valued at about $1,296,000. Susquehanna Fundamental Investments LLC acquired a new stake in Vanda Pharmaceuticals in the fourth quarter valued at approximately $1,221,000. Dimensional Fund Advisors LP increased its holdings in shares of Vanda Pharmaceuticals by 10.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,488,519 shares of the biopharmaceutical company’s stock valued at $11,920,000 after acquiring an additional 227,428 shares in the last quarter. Monaco Asset Management SAM raised its position in shares of Vanda Pharmaceuticals by 92.8% during the fourth quarter. Monaco Asset Management SAM now owns 392,262 shares of the biopharmaceutical company’s stock worth $1,879,000 after purchasing an additional 188,836 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Vanda Pharmaceuticals by 108.9% in the 4th quarter. JPMorgan Chase & Co. now owns 335,741 shares of the biopharmaceutical company’s stock worth $1,608,000 after purchasing an additional 175,019 shares in the last quarter. 88.14% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Trading Down 6.2%

Shares of NASDAQ:VNDA opened at $3.96 on Monday. The stock has a market cap of $233.38 million, a PE ratio of -12.38 and a beta of 0.69. The stock’s fifty day simple moving average is $4.52 and its two-hundred day simple moving average is $4.65. Vanda Pharmaceuticals Inc. has a 1-year low of $3.85 and a 1-year high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The company had revenue of $50.04 million during the quarter, compared to the consensus estimate of $45.13 million. On average, sell-side analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

VNDA has been the subject of a number of recent research reports. StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a “hold” rating for the company. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th.

Insider Buying and Selling at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of Vanda Pharmaceuticals stock in a transaction on Friday, February 28th. The stock was purchased at an average price of $4.76 per share, for a total transaction of $47,600.00. Following the purchase, the chief executive officer now directly owns 2,361,730 shares of the company’s stock, valued at $11,241,834.80. This trade represents a 0.43% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last 90 days, insiders bought 32,000 shares of company stock worth $151,180. Insiders own 10.00% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.